- City of Hope Cancer Centre By Saul J. Priceman, PhD -

For a full list of publications click here

AACR Journals | Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Kim SI, Park AK, Chaurasiya S, Kang S, Lu J, Yang A, Sivanandam V, Zhang Z, Woo Y, Priceman SJ, Fong Y, Warner SG.Mol Cancer Ther. 2021 Jan;20(1):173-182. doi: 10.1158/1535-7163.MCT-20-0405. Epub 2020 Dec 1.PMID: 33262221

Science Translational Medicine | Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, Jeang B, Chang WC, Chen NG, Thomas SH, Forman SJ, Priceman SJ. Sci Transl Med. 2020 Sep 2;12(559):eaaz1863. doi: 10.1126/scitranslmed.aaz1863.PMID: 32878978

Cancer Treatment Research | CAR T Cell Therapy Progress and Challenges for Solid Tumors. Stern LA, Jonsson VD, Priceman SJ. Cancer Treat Res. 2020;180:297-326. doi: 10.1007/978-3-030-38862-1_11.PMID: 32215875

Current Opinion in Oncology | Smart CARs engineered for cancer immunotherapy. Priceman SJ, Forman SJ, Brown CE.Curr Opin Oncol. 2015 Nov;27(6):466-74. doi: 10.1097/CCO.0000000000000232.PMID: 26352543 Free PMC article. Review.


- City of Hope Cancer Centre By Professor Yuman Fong -

For a full list of publications click here

Therapeutic Advances in Medical Oncology | CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study Yuan Yuan, Colt Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Lin, Helen Chang, Leslie Mi Ok Chong, Amanda Seiz, Monil Shah, W. Hans Meisen, Aileen Tang, Norma Martinez, Wichanee Pickett, Mireya Murga, Susan E. Yost, Daphne Stewart, Jianying Zhang, Nicholas Ede, Badri Modi, Jonathan Kessler, Jamie Rand, and Yuman Fong

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models

MDPI Cancers Journal | Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges 26 June 2020 This article belongs to the Special Issue Oncolytic Virus Therapy Against Cancer

- Ohio State University by Professor Pravin Kaumaya -

For a full list of publications click here

Cancer vaccines hold potential in the immuno-oncology space as an alternative to monoclonal antibodies or other approaches – but why have they not yet gained more traction in the immuno-oncology space? Professor and director of vaccine research at The Ohio State University, Pravin Kaumaya, once described B cell epitope cancer vaccines as a “new paradigm for combination immunotherapies”.

Roisin McGuigan, Editor, Immuno-Oncology Insights, speaks to Pravin TP Kaumaya, Professor and Director of Vaccine Research at The Ohio State University

Guo, L., Kaumaya, P.T.P. First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations. British Journal of Cancer (2021).

Pravin T. P. Kaumaya , Linlin Guo , Jay Overholser , Manuel L. Penichet & Tanios Bekaii-Saab, Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model, ONCOIMMUNOLOGY 2020, VOL. 9, NO. 1, e1818437.

PT Kaumaya, B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine, Future Oncol. 2020 Aug;16(23):1767-1791

- Medical University of Vienna by Professor Dr Ursula Wiedermann-

For a full list of publications click here

Annals of Oncology, VOLUME 34, SUPPLEMENT 1, S4, JUNE 2023 | Tobias, J etal, PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome

J. Tobias, E. Garner-Spitzer, M. Drini & U. Wiedermann ESMO OPEN Cancer Horizons | Vaccination against Her-2/neu, with focus on peptide-based vaccines

J. Tobias, P. Steinberger, M. Drinic & U. Wiedermann ESMO OPEN Cancer Horizons | Emerging targets for anticancer vaccination: PD-1

Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, Marina Maglakelidze, Iurie Bulat, Arunee Dechaphunkul, Wichit Arpornwirat, Chaiyut Charoentum, Chia-Jui Yen, Thomas Yau, Suebpong - Tanasanvimon, Jedzada Maneechavakajorn, Aumkhae Sookprasert, Li-Yuan Bai, Wen-Chi Chou, Teerapat Ungtrakul, Mirjana Drinić, Joshua Tobias, Christoph C Zielinski, Leslie Chong, Nicholas J Ede, Mark T Marino and Anthony J Good. Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001.

Clin Cancer Res April 28 2021 DOI: 10.1158/1078-0432.CCR-20-3742

Joshua Tobias, Claire Battin, Annika De Sousa Linhares, Michael Lebens, Karin Baier, Katharina Ambroz, Mirjana Drinic ́ , Sandra Högler, Aleksandra Inic-Kanada, Erika Garner-Spitzer, Matthias Preusser, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Peter Steinberger and Ursula Wiedermann , A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors, Front. Immunol., 27 May 2020

Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, Wiedermann U. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer. 2017 Feb 9;17(1):118. doi: 10.1186/s12885-017-3098-7

Wiedermann U and C.C. Zielinski. Vaccination for prevention and treatment of breast cancer. Breast Cancer Res Treat. 2013 Feb;138(1):1-12

Wiedermann U, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer. R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner, C.C. Zielinski. 2010. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 119 (3):673-83.

Wagner S, C. Krepler, D. Allwardt, J. Latzka, S. Strommer, O. Scheiner, H. Pehamberger, U. Wiedermann, C. Hafner, and H. Breiteneder. 2008. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res.;14(24):8178-83.

Wagner, S.; J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. 2007 Jan 3; 106(1):29-38.

Brämswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res. 2007 Nov 1;13(21):6501-8.

Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 2007 Apr 1;67(7):3406-11.

Hafner, C.; H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2005. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer, 114:426.

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.

Jasinska J, WagnerS, RadauerC, SedivyR, BrodowiczT, WiltschkeC, Breiteneder H, Pehamberger H, Scheiner O, WiedermannU*, Zielinski CC. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int. J. Cancer. 2003. 20; 107:976-83.